List of Excipients in Branded Drug TASIGNA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	TASIGNA	nilotinib	0078-0526	CROSPOVIDONE
Novartis Pharmaceuticals Corporation	TASIGNA	nilotinib	0078-0526	FERRIC OXIDE RED
Novartis Pharmaceuticals Corporation	TASIGNA	nilotinib	0078-0526	FERRIC OXIDE YELLOW
Novartis Pharmaceuticals Corporation	TASIGNA	nilotinib	0078-0526	GELATIN
Novartis Pharmaceuticals Corporation	TASIGNA	nilotinib	0078-0526	LACTOSE MONOHYDRATE
Novartis Pharmaceuticals Corporation	TASIGNA	nilotinib	0078-0526	MAGNESIUM STEARATE

Tasigna Excipient Strategy and Commercial Opportunities: Nilotinib Formulation, Generic Entry, and Patent Risks

Last updated: September 7, 2026

Tasigna is Novartis’s oral nilotinib product for Philadelphia chromosome-positive chronic myeloid leukemia. Its commercial formulation is a hard gelatin capsule containing a relatively conventional solid-dose excipient system: lactose monohydrate, microcrystalline cellulose, crospovidone, sodium starch glycolate, poloxamer 188, colloidal silicon dioxide, magnesium stearate, and capsule-shell colorants, among other materials listed in the FDA prescribing information.[1]

The strongest excipient opportunities are not likely to come from simple substitution of one conventional filler or disintegrant. Commercial value is higher in four areas: improving nilotinib dissolution, reducing food-effect sensitivity, enabling pediatric or geriatric administration, and creating differentiated formulations that support new intellectual property or regulatory positioning.

What excipients are used in Tasigna capsules?

Tasigna uses a conventional immediate-release capsule platform with excipients that support powder processing, capsule filling, disintegration, and drug dispersion.

Tasigna inactive ingredients

Formulation function	Tasigna excipient or component	Commercial relevance
Diluent and compressibility aid	Lactose monohydrate	Low-cost bulk excipient; creates lactose-intolerance and compatibility considerations
Diluent and processing aid	Microcrystalline cellulose	Improves powder structure and capsule-fill consistency
Disintegrant	Crospovidone	Promotes rapid breakup of the capsule contents
Disintegrant	Sodium starch glycolate	Supports liquid uptake and disintegration
Surfactant or wetting aid	Poloxamer 188	Supports dispersion of poorly water-soluble nilotinib
Glidant	Colloidal silicon dioxide	Improves powder flow and content uniformity
Lubricant	Magnesium stearate	Reduces adhesion during manufacturing
Capsule shell	Gelatin	Standard hard-capsule shell
Colorants and opacifiers	Titanium dioxide and iron oxides, depending on strength and presentation	Supports product identification and light protection

The exact excipient composition can differ by strength and market. The FDA-approved prescribing information and the relevant national product information should control any formulation comparison.[1,2]

Nilotinib has limited aqueous solubility and its absorption is strongly affected by food. The FDA label instructs patients to take Tasigna on an empty stomach and avoid food for specified periods before and after dosing.[1] That restriction creates the central formulation opportunity: improve exposure consistency without increasing toxicity or compromising the drug’s pharmacokinetic profile.

What formulation problems create commercial opportunities for Tasigna?

The principal technical issues are food effect, dissolution behavior, dose administration, capsule swallowing, and long-term manufacturing consistency.

Food-effect reduction

Nilotinib exposure increases substantially when administered with food. A formulation that provides reproducible absorption under fed and fasted conditions could have commercial value, particularly if supported by clinical pharmacokinetic data.

Potential approaches include:

• Amorphous solid dispersions using polymers such as copovidone, hypromellose, or hypromellose acetate succinate.
• Surfactant-containing lipid or self-emulsifying systems.
• Spray-dried dispersions.
• Nanocrystal or nanosuspension platforms.
• pH-modifying excipients that improve dissolution in the gastrointestinal tract.
• Polymer-lipid combinations that limit precipitation after dissolution.

The technical challenge is balancing increased dissolution with nilotinib’s narrow safety margin. Higher or more variable exposure could increase risks associated with QT prolongation, hepatic toxicity, or other adverse events identified in the label.[1]

Dissolution and bioequivalence

A generic product must demonstrate pharmaceutical equivalence and bioequivalence under the applicable abbreviated approval pathway. For immediate-release capsules, differences in particle size, polymorphic form, granulation, surfactant level, lubricant concentration, and disintegrant selection can materially affect dissolution.

A substitute excipient system should be assessed for:

1. Comparative dissolution across multiple pH conditions.
2. Fed and fasted bioequivalence.
3. Stability under accelerated and long-term conditions.
4. Capsule-fill weight variation.
5. Content uniformity across commercial-scale batches.
6. Nitrosamine and elemental-impurity risk.
7. Compatibility with nilotinib and capsule-shell materials.

The best generic excipient strategy is usually one that remains close to the reference product’s functional profile while avoiding unnecessary formulation complexity.

Which excipient technologies could support a differentiated Tasigna product?

A differentiated product would need a clinically or commercially meaningful advantage. Merely replacing lactose with mannitol, or crospovidone with another disintegrant, is unlikely to create durable market differentiation by itself.

Lactose-free and low-allergen formulations

Lactose-free Tasigna capsules could target patients with lactose intolerance, although the clinical value would depend on the lactose quantity in the reference product and the prevalence of relevant symptoms. Mannitol, dibasic calcium phosphate, silicified microcrystalline cellulose, or directly compressible excipient blends could replace lactose.

The principal risks are altered dissolution, different moisture behavior, and weaker regulatory differentiation. A lactose-free product could still be commercially useful in markets where physicians or patients prefer a lactose-free oral oncology product, but the opportunity is likely incremental rather than transformational.

Smaller capsules and dose flexibility

Tasigna is available in 150 mg and 200 mg capsules.[1] A smaller capsule, multiparticulate system, or sprinkle-compatible presentation could improve administration for patients with dysphagia.

Potential platforms include:

• Mini-tablets filled into capsules.
• Multiparticulates coated for immediate release.
• Smaller high-load capsules.
• Oral powder packaged in unit-dose sachets.
• A liquid or dispersible formulation for patients unable to swallow capsules.

Dose flexibility is commercially relevant because nilotinib treatment can involve dose reductions, interruptions, and treatment adjustments. Any new presentation would need to preserve accurate dosing and avoid unintended crushing or manipulation.

Pediatric formulation

A pediatric formulation could support treatment in children and adolescents with suitable indications, subject to clinical development and regulatory requirements. A powder-for-suspension or dispersible dosage form would be more practical than a conventional adult capsule.

Key formulation considerations include:

• Avoidance of excessive bitterness.
• Low dosing volume.
• Uniform drug distribution after reconstitution.
• Short in-use stability period.
• Protection against accidental exposure.
• Compatibility with common administration devices.
• Control of systemic exposure relative to the capsule.

Pediatric development can create regulatory value through pediatric exclusivity where the statutory conditions are met, but the commercial opportunity depends on the addressable pediatric population and clinical program cost.[3]

What patents protect Tasigna and its formulation?

Tasigna’s patent position has historically included nilotinib compound protection, pharmaceutical-composition claims, and possible formulation or use claims. The central compound patent protection has expired or reached the end of its original term in the United States, allowing generic competition to develop after the relevant patent and regulatory barriers ended.

Patent categories relevant to nilotinib

Patent category	Typical claim scope	Excipient-strategy impact
Compound patent	Nilotinib chemical entity and related compounds	Generally expired or near-expired in major markets
Salt or crystalline-form patent	Solid forms, polymorphs, or specific physical forms	May constrain API sourcing or solid-form selection
Composition patent	Nilotinib combined with defined excipient ranges	Can affect generic formulation design
Dissolution or dispersion patent	Amorphous dispersions, particle size, surfactant systems	Relevant to differentiated formulations
Method-of-use patent	Treatment of CML or dosing regimens	Can affect labeling and skinny-label strategies
Manufacturing patent	API synthesis, purification, crystallization, or milling	May create noninfringement and supply-chain issues
Pediatric or liquid-form patent	New dosage forms or administration methods	Potential basis for lifecycle management

Patent expiration must be determined patent by patent, jurisdiction by jurisdiction, and with any patent-term adjustment, patent-term extension, disclaimer, terminal disclaimer, or regulatory exclusivity included. The FDA Orange Book should be used for listed U.S. patents, while WIPO PATENTSCOPE, the European Patent Register, and national registers should be used for foreign rights.[4-6]

What is the Orange Book status of Tasigna?

The Orange Book determines which patents and exclusivities are listed for approved U.S. drug products. Tasigna’s commercial position should be analyzed separately for the 150 mg and 200 mg capsules, because listed patents, strengths, and generic approvals can differ.

A current Orange Book review should cover:

• Reference-listed drug status.
• Listed patent numbers and expiration dates.
• Pediatric exclusivity.
• Generic approvals by strength.
• Therapeutic-equivalence codes.
• Whether a generic applicant has made a Paragraph IV certification.
• Whether any 30-month stay or litigation-related listing applies.

A Paragraph IV certification can trigger patent litigation by the reference-product sponsor. If the patent holder sues within the statutory period, FDA approval may be stayed for up to 30 months, subject to statutory exceptions and court developments.[7] The commercial effect depends on whether the challenged patent is compound, formulation, method-of-use, or manufacturing-related.

Which companies are challenging Tasigna exclusivity?

Generic competition for nilotinib can come from companies filing abbreviated new drug applications, but the commercial impact depends on approval status, manufacturing capacity, litigation outcomes, and launch timing.

Potential competitor groups include:

• Large generic manufacturers with oncology portfolios.
• API-integrated suppliers.
• Regional manufacturers seeking approval outside the United States.
• Specialty generic companies targeting high-cost oral oncology products.
• Contract manufacturers licensing or supplying nilotinib formulations.

A generic entrant with a conventional immediate-release capsule may compete primarily on price. A company with a food-effect-reduced formulation, smaller capsule, or pediatric presentation could compete through differentiation and potentially avoid direct price competition.

Publicly available FDA, court, and regulatory records should be used to identify current Paragraph IV filers and litigation status. Patent challenges should not be inferred solely from a generic product appearing in a commercial database.

How strong is the Tasigna patent estate?

The patent estate is strongest where claims cover the nilotinib molecule, a required solid form, or a formulation that produces a distinctive and clinically relevant pharmacokinetic profile. It is weaker where claims rely on broad conventional excipient combinations or routine ranges that can be designed around.

Strength factors

• A claim requires a specific nilotinib solid form that is difficult to avoid.
• The formulation shows an unexpected dissolution or exposure advantage.
• The claim is supported by comparative clinical or pharmacokinetic data.
• The patent covers a commercially important dosage form.
• The patent has substantial remaining term after regulatory approval.
• The patent owner can enforce the claim against a practical generic design.

Weakness factors

• The claim recites routine excipients without unexpected results.
• The same formulation is disclosed in earlier solid-dosage-form literature.
• A generic can substitute a different polymer, disintegrant, or capsule shell.
• The patent relies on a narrow method-of-use limitation.
• The claim is vulnerable to written-description, enablement, obviousness, or anticipation challenges.

For excipient suppliers, the highest-value strategy is often to generate data demonstrating a technical effect, such as reduced food sensitivity, improved dissolution at physiologic pH, improved stability, or reduced dose variability. Data can support customer formulation patents and strengthen freedom-to-operate positions.

What manufacturing and intellectual-property barriers affect nilotinib?

Manufacturing barriers are more significant for advanced formulations than for conventional capsules.

API and solid-form control

Nilotinib API manufacturing requires control of impurity profile, residual solvents, particle-size distribution, polymorphism, and batch-to-batch physical properties. A formulation that depends on a particular particle-size distribution or crystal form can create a supply constraint.

Excipient compatibility

Excipient selection should address:

• Peroxide formation in polymers and surfactants.
• Moisture uptake by disintegrants and capsule shells.
• Interaction between nilotinib and magnesium stearate.
• Colorant and light-protection requirements.
• Gelatin cross-linking and delayed dissolution.
• Extractables and leachables in liquid or dispersible presentations.

Regulatory change control

Changing an excipient in an approved generic product can require comparative dissolution, stability, and potentially additional bioequivalence data. The regulatory burden depends on the nature and extent of the change. Excipient suppliers with established pharmaceutical-grade documentation, compendial compliance, elemental-impurity controls, and global regulatory support have a stronger commercial position.

How does Tasigna compare with competing CML drugs?

Tasigna competes with other BCR-ABL tyrosine kinase inhibitors, including imatinib, dasatinib, bosutinib, and ponatinib. Excipient opportunities differ across these products because each has a distinct solubility, food-effect, safety, and dosing profile.

Product	Active ingredient	Formulation opportunity
Tasigna	Nilotinib	Food-effect reduction, improved dissolution, pediatric or dysphagia-friendly presentation
Gleevec/Glivec	Imatinib	Cost-efficient generic manufacture and patient-friendly solid dosage forms
Sprycel	Dasatinib	Low-dose content uniformity, dissolution control, pediatric administration
Bosulif	Bosutinib	Food-effect and tolerability management
Iclusig	Ponatinib	Low-dose accuracy, stability, and exposure control

Nilotinib’s food restriction gives it a more visible formulation disadvantage than many competing products. That disadvantage is also the clearest lifecycle-management opportunity.

What licensing deals could create commercial value?

Commercial opportunities may arise through licensing of:

• A nilotinib amorphous dispersion.
• A food-effect-reduced formulation.
• A pediatric suspension or dispersible product.
• A high-throughput capsule-filling platform.
• A proprietary co-processed excipient blend.
• A regional generic formulation with regulatory dossiers.
• An API and formulation package for emerging markets.

A supplier should seek claims and data that can be licensed across multiple products rather than relying solely on Tasigna. A platform that improves dissolution for several poorly soluble kinase inhibitors has greater partnering value than a formulation optimized only for nilotinib.

What generic launch scenarios exist for Tasigna?

Three launch scenarios are commercially relevant.

Conventional generic launch

A standard capsule launches after patent and regulatory barriers are cleared. Price erosion is likely to be rapid if several approved suppliers enter simultaneously.

Limited generic launch

One or two manufacturers enter because of difficult bioequivalence, API supply constraints, or unresolved formulation patents. Price erosion is slower, and reliable supply has greater value.

Differentiated lifecycle launch

A company launches a pediatric, lactose-free, smaller-capsule, or food-effect-reduced product. This approach requires additional development but can protect margins through clinical utility rather than price alone.

What is the revenue exposure for Tasigna?

Tasigna revenue is exposed to generic substitution after loss of core exclusivity. The actual decline depends on:

• Number of approved generic suppliers.
• Payer substitution rules.
• Hospital and specialty-pharmacy contracts.
• Generic launch timing.
• Remaining use in newly diagnosed and resistant CML.
• Physician preference for established products.
• Availability of competing BCR-ABL inhibitors.
• Geographic differences in reimbursement and patent enforcement.

Novartis’s annual reports provide historical Tasigna sales and geographic revenue information.[8] A revenue model should separate originator erosion from total nilotinib-market growth, because generic volume can increase while originator revenue falls.

Key Takeaways

• Tasigna is an immediate-release nilotinib capsule using conventional diluents, disintegrants, surfactant, glidant, lubricant, and gelatin-shell components.
• Food-effect reduction is the most commercially meaningful formulation opportunity.
• Generic manufacturers can compete with conventional capsules, but differentiated formulations may preserve pricing power.
• Lactose-free, smaller-capsule, pediatric, and dysphagia-friendly presentations are practical lifecycle opportunities.
• Patent analysis must distinguish compound, solid-form, formulation, method-of-use, and manufacturing claims.
• The Orange Book is the primary U.S. source for listed patents, exclusivities, generic approvals, and Paragraph IV-related information.
• Excipient suppliers gain the most value by generating comparative data that support formulation performance and patentability.
• Nilotinib formulation development must control exposure variability because increased absorption can raise safety risks.

FAQs

Can Tasigna be reformulated as a tablet?

Yes. A tablet could be developed, but it would require demonstration of equivalent exposure, dissolution, stability, and dose accuracy. A tablet would not automatically avoid formulation patents or food-effect limitations.

Which excipient is most important for nilotinib dissolution?

Poloxamer 188 and the disintegrant system are important, but dissolution depends on the full formulation, including API particle size, solid form, wetting, polymer interactions, and manufacturing process.

Does a lactose-free nilotinib product have strong commercial potential?

It has targeted potential. The opportunity is stronger when combined with smaller capsules, improved administration, or documented tolerability benefits. Lactose replacement alone is unlikely to create a major market advantage.

Can an excipient supplier patent a nilotinib formulation?

Yes. Patentability depends on novelty, inventive step or nonobviousness, enablement, and claim scope. A patent is more defensible when the formulation produces unexpected dissolution, pharmacokinetic, stability, or food-effect results.

Is a pediatric Tasigna formulation commercially attractive?

Potentially. The opportunity depends on the pediatric treatment population, regulatory requirements, dosing flexibility, taste masking, administration volume, and the remaining exclusivity period in each market.

References

1. U.S. Food and Drug Administration. (2023). Tasigna (nilotinib) prescribing information. Novartis Pharmaceuticals Corporation. https://www.accessdata.fda.gov
2. European Medicines Agency. (2023). Tasigna: European public assessment report and product information. https://www.ema.europa.eu
3. U.S. Food and Drug Administration. (2023). Pediatric exclusivity. https://www.fda.gov
4. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
5. World Intellectual Property Organization. (2025). PATENTSCOPE database. https://patentscope.wipo.int
6. European Patent Office. (2025). European Patent Register. https://register.epo.org
7. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and Paragraph IV certifications. https://www.fda.gov
8. Novartis AG. (2024). Annual report 2023. https://www.novartis.com/investors/financial-data/annual-report-selector